Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (221-230 of 377) with videos related to

Pageof 38
Sort By:
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Plos One|December 7, 2013
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trialYasmin Issa-Nummer, Silvia Darb-Esfahani, Sibylle Loibl, et al.
Frontiers in Oncology|September 22, 2022
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trialKatya Galactionova, Sibylle Loibl, Paola Salari, et al.
JAMA|November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical TrialTheodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
Breast Cancer Research : BCR|May 12, 2019
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixtoElena Laakmann, Isabell Witzel, Peter A Fasching, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.
Geburtshilfe Und Frauenheilkunde|July 31, 2018
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among PhysiciansPaul Gass, Michael Untch, Volkmar Müller, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
Breast Cancer Research and Treatment|February 8, 2014
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinomaSibylle Loibl, Cristina Volz, Christine Mau, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 23, 2024
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspectiveDavid Krug, Maggie Banys-Paluchowski, Sara Y Brucker, et al.
Pageof 38

Showing results (221-230 of 377) with videos related to

Sort By:
Pageof 38
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Plos One|December 7, 2013
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trialYasmin Issa-Nummer, Silvia Darb-Esfahani, Sibylle Loibl, et al.
Frontiers in Oncology|September 22, 2022
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trialKatya Galactionova, Sibylle Loibl, Paola Salari, et al.
JAMA|November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical TrialTheodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
Breast Cancer Research : BCR|May 12, 2019
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixtoElena Laakmann, Isabell Witzel, Peter A Fasching, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.
Geburtshilfe Und Frauenheilkunde|July 31, 2018
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among PhysiciansPaul Gass, Michael Untch, Volkmar Müller, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
Breast Cancer Research and Treatment|February 8, 2014
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinomaSibylle Loibl, Cristina Volz, Christine Mau, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 23, 2024
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspectiveDavid Krug, Maggie Banys-Paluchowski, Sara Y Brucker, et al.
Pageof 38